Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1Terminated 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 10Thoracic 4Gastrointestinal 4Head & Neck 3CNS 3Plasma cell 2Other hematologic neoplasm 2Lymphoid 2Gynecologic 2Breast 2Sarcoma 1Other solid neoplasm 1Genitourinary 1

Conditions

Gastrointestinal Stromal Tumors 1

Interventions

Cyclophosphamide 22Specimen Handling 20Magnetic Resonance Spectroscopy 20pembrolizumab 18Nivolumab 18Radiotherapy 17Biopsy 16Doxorubicin 15Temozolomide 14Radiation 14X-Rays 9Irinotecan 9Ipilimumab 9Ifosfamide 9fludarabine 8Phantoms, Imaging 8Etoposide 8cabozantinib 7Vincristine 7Carboplatin 7Bevacizumab 7regorafenib 6Sirolimus 6palbociclib 5olaparib 5fludarabine phosphate 5durvalumab 5Vinorelbine 5Sunitinib 5Radiosurgery 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × binimetinib × Sarcoma × Clear all
NCT01991379 2025-12-04

MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)

Memorial Sloan Kettering Cancer Center

Phase 1/2 Active not recruiting
75 enrolled
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡